Procter & Gamble is acquiring Thorne Health Technologies to bolster its health-and-wellness portfolio, with an official announcement expected this Tuesday. Shailesh Jejurikar described Thorne as well-run and longstanding, suggesting meaningful revenue synergy potential through expanded distribution of supplements like Magnesium Glycinate and Ginseng Plus. The move expands P&G's health brands alongside Vicks and Oral-B.
Procter & Gamble reported a mixed fiscal fourth quarter: revenue $21.2B, modest miss versus $21.38B, and adjusted EPS of $1.43 vs $1.41. Net income declined to $3.04B ($1.26 per share) from $3.62B a year earlier. CEO Shailesh Jejurikar will become board chair on Aug. 1, signaling governance continuity as demand remains challenging.
Procter & Gamble's Q3 earnings of $1.59 per share and $21.235 billion in sales surpassed analyst estimates, highlighting robust financial performance. This strong showing may bolster investor confidence and support stock price growth in the near term.
Procter & Gamble has warned of a $150 million annual profit decline due to increased input costs from the Middle East conflict. Despite this, robust demand for its premium hair and skin care products allowed the company to surpass quarterly expectations, but margins could remain pressured moving forward.
Analysts predict Procter & Gamble's Q3 revenue will rise to $20.53 billion amid competitive pressures from retailers shifting to private labels. With expectations of steady earnings per share growth, PG's guidance will be closely monitored for indications of future performance and market share stability.
